+ All Categories
Home > Documents > ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can...

ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can...

Date post: 30-Dec-2019
Category:
Upload: others
View: 2 times
Download: 0 times
Share this document with a friend
29
ARV Resistance 1
Transcript
Page 1: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

ARV Resistance

1

Page 2: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Learning Objectives

Define drug resistanceIdentify factors that influence drug resistance. Identify strategies for minimizing development of

drug resistance. Identify strategies for responding to detection of

moderate to high levels of drug resistant HIV.

Page 3: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Impact of drug resistance

• Why is it important to measure drug resistance?

• How does it impact the success of large-scale treatment programs?

Presenter
Presentation Notes
Transition to next section. Note that we will try to answer these questions.
Page 4: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

What is ARV drug resistance?

Drugs no longer block virus replication Cause: Mutations in the viral genome

One or more: Specific for an antiviral drug OR Affecting related drugs (cross-resistance)

How much resistance? Which drugs? Depends on type and number of mutations

Presenter
Presentation Notes
Present definition of drug resistance and its causes: Reduced susceptibility of the virus to a specific antiviral drug (drug is less effective in blocking virus replication) Caused by mutations in the viral genome, generally located in the gene encoding the protein targeted by the antiviral drug Mutations can be specific for an antiviral drug or lead to reduced susceptibility to related drugs (cross-resistance) Magnitude of resistance imparted depends on mutations In some cases (e.g. 3TC or nevirapine) a single mutation may result in a completely resistant virus (low genetic barrier drugs) In some cases multiple mutations are needed (e.g. lopinavir or darunavir) to reduce drug activity (high genetic barrier drugs) Accumulation of mutations may result in increase in the level of resistance (AZT or PIs)
Page 5: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Types of drug resistance

Acquired drug resistance Develops when patients interrupt their treatment, do

not take it according to prescription, or the drugs are not absorbed properly

Transmitted drug resistance People are infected from others who had HIV drug

resistance and that carry resistant

Page 6: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once
Presenter
Presentation Notes
EXPLAIN Globally, there are an estimated 36.9 million adults and children living with HIV, as measured in 2014. In Malawi, there are approximately 980,000 PLWHIV with an estimated 50% on ART.
Page 7: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

HIV Drug Resistance - unavoidable

HIV DR is an inevitable consequence of ART, influenced by: Ability of regimens to suppress replication completely Adherence and tolerability of regimens "Genetic barrier" to resistance Relative fitness of resistant variant(s) Pharmacokinetics (IQ) Availability/continuity of drug supply Removal of barriers to access to care

Therefore, efforts to minimize HIV DR should be focused on these factors

Presenter
Presentation Notes
Emphasize that while it is impossible to eliminate or completely prevent drug resistance, it is possible and necessary to minimize drug resistance. Barriers = transportation, costs.
Page 8: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Need for population-based therapies

1• Need for rapid scale-up• Limitations in health infrastructure, trained

personnel, facilities, lab capacity, drug transport and storage

2• Need for standardized simplified treatment

protocols• Regimen selection not by clinicians but by

national policy—first-line and second-line regimens

Presenter
Presentation Notes
Present information on the need to have an effective but limited set of treatment options when resources are scarce: Rapid scale-up of antiretroviral therapy is an international priority. Many countries have targeted coverage for 80% of individuals in need of treatment. Making this scale-up more challenging are infrastructure limitations. Given these constraints, the public health approach to extend ART rapidly to the maximum number of people relies on standardized simplified treatment protocols, standardized management approaches, and decentralized service delivery. The decision on an effective first-line regimen (usually one NNRTI and two NRTIs) and a second-line regimen (usually a PI boosted by ritonavir and two NRTIs) is made at the national level, because there is not the money, equipment, facilities, or people to support individually-prescribed regimens. Regimen selection is based on the unique challenges (availability, cost) of that country.
Page 9: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Need to maintain effectiveness

1• Limited number of

regimens available

2• Need to minimize drug

resistance

Presenter
Presentation Notes
Present the importance of minimizing drug resistance given the factors previously described: With standardized simplified treatment protocols across a large number of people, the emergence and spread of drug resistance can have extensive and costly consequences. At the national level, you can minimize drug resistance by carefully monitoring it and by promoting adherence to the recommended regimen.
Page 10: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Drug resistance and HIV

HIV… evolves rapidly within human body has a high replication rate has a high mutation rate

Resistant strains can emerge within days if drug pressure is not sufficient to suppress replication. Resistant strains persist indefinitely and can re-emerge if

same drugs are stopped and restarted.

Presenter
Presentation Notes
Present factors related to this virus in particular that lead to drug resistance in a population.
Page 11: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Review

Why is it important to measure drug resistance?How does it impact the success of large-scale treatment

programs?

Page 12: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Factors that influence development of drug resistance

• What regimens influence drug resistance?• What patient factors influence drug resistance?• What public health approaches influence drug

resistance?

Presenter
Presentation Notes
Transition to next section. Note that we will try to answer these questions.
Page 13: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

In which conditions is DR more likely?

Treatment with <3 drugs Inappropriate selection of drugs Adding one drug to a failing regimen Interruption of treatment (even for a few days) Prolonging a failing regimen

Page 14: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Virus related factors influencing resistance

High replication rate of HIV Turnover of 10 billion virions daily

Frequent errors made during replication

High mutation rate 20 million mutations daily

Latent reservoirs of HIV Enable drug resistant HIV to hide for 20-30 years

Presenter
Presentation Notes
ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can be activated many years later. Once a patient is resistant to an ARV drug, that drug will probably be ineffective in the future. HIV does not “forgive” treatment errors or non-adherence.
Page 15: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Resistance can develop quickly, depending on the viral load

Viral Load Days Before Mutation Arises

300,000 0.1

30,000 1

3,000 10

300 100

30 1,000Siliciano, 2002

Page 16: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Drug related factors influencing resistance

Inadequate potency (strength) Drug interactions leading to suboptimal drug

levels Inadequate durability of drug potency (e.g., dual

therapy) Poor tolerability Inconvenience of regimen

Presenter
Presentation Notes
Viral escape depends on the rate of residual viral replication, which is increased if there is: Inadequate potency, e.g. mono and dual therapy. With a more potent regimen, there is decreased replication and decreased chance to develop drug resistance mutations. what are the drug interactions to be concerned with here?
Page 17: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Adequate Drug Levels are Crucial to Control HIV Replication

High drug levels delay or prevent development of resistance.

Low drug levels encourage viral replication, ARV resistance, viral rebound and ultimate clinical deterioration.

Page 18: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Mutations and Resistance

For certain ARVs, only one mutation is needed to stop the drug from working.

For other ARVs, multiple, step-wise mutations must occur before the drug loses affect.

Presenter
Presentation Notes
some arvs are stronger than others and may require slightly less strict adherence than others. however, still aim for 95% for all
Page 19: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

In which conditions is DR less likely?

Medication Factors:

All patients treated with 3 or more drugsUse of appropriate drug regimens Can reliably suppress HIV replication to levels of <50

copies/mlUse of fixed-dose combinations to support adherence

Page 20: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

In which conditions is DR less likely?

Systems Factors:

Limited number of regimens Trained personnel, low turnover Supervision and monitoring Adequate lab services Drug supply and delivery systems

Page 21: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

In which conditions is DR less likely?

Patient Factors:

Adherence to treatment regimen Avoiding interruption of treatment, even if only a few

days Regular follow-up (going to clinic) Staying on uninterrupted first-line ART as long as

possible

Page 22: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Programmatic factors affecting patient adherence

Cost of treatment to patient (not only money, but time) Distance patient must travel to get treatment Supply interruptions Availability of second-line regimens for patients whose

first-line regimens fail Timing of use of second-line regimens

Presenter
Presentation Notes
Present information on factors that are associated with avoiding widespread drug resistance.
Page 23: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Discussion

What regimens influence drug resistance?What patient factors influence drug resistance?What public health approaches influence drug

resistance?

Page 24: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Reflection

What regimens do we use in our country?What systematic and programmatic challenges do we

face?

Presenter
Presentation Notes
Ask participants to write their own answers to these questions in the blank space on their handouts.
Page 25: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Minimizing drug resistance

What can countries do to minimize or suppress drug resistance?

Presenter
Presentation Notes
Transition to next section. Note that we will try to answer these questions.
Page 26: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Strengthen existing programmes that minimize HIV DR

Support for adherence and follow-up THIS IS YOU! Removal of barriers to ART access Drug supply continuity at the individual, ART site, and

national levels

Page 27: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Monitor early warning indicators

Routine collection of medical and pharmacy recordsMonitor for factors associated with HIV DR prevention or

emergence Extent to which prescribing practices meet national and

international guidelines % of patients still on first-line; % lost to follow-up % patients with timely medication pick up and clinical follow-

up Drug supply continuity at site Adherence and viral load THIS IS YOU!

Page 28: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

HIV DR Early Warning Indicators (EWIs)

Prescribing practices

Proportion lost to follow-up during the

first 12 months of ARTPatient retention on first-line ART

On-time ARV drug pick up

ART appointment-

keeping

Drug supply continuity

Site-level ART Program Function

Viral load suppression @ 6

months

Pill count/ adherence

Presenter
Presentation Notes
Present: This side shows ix different recommended EWIs (in red) and two additional EWIs (in blue). These blue ones are good, but need good infrastructures in place to gather the data. Emphasize: On time pickup: % of ART patients picking up prescribed ARV drugs on time (before previous drugs run out) Drug supply: ART stops, substitutions, and switches due to ARV shortages during a specified period OR % of months during a year with no antiretroviral drug stock outages
Page 29: ARV Resistance...ARV resistance, once it develops, is probably life-long, since resistant HIV can hide in latent cellular reservoirs, which can\ഠbe activated many years later. Once

Key Messages

Impact of HIV Drug Resistance Factors that Influence Development of Drug ResistanceHow to Minimize Drug Resistance


Recommended